티스캔 테라퓨틱스(TCRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.78 (+0.88%), 시가총액 $0.07B, 52주 범위 $0.90 ~ $2.52.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the compan
티스캔 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
티스캔 테라퓨틱스의 현재 주가는 $0.78 (+0.88%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
티스캔 테라퓨틱스의 시가총액은 약 $0.07B입니다.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The compa